Skip to main navigation

News
Investors
Careers
Contact

About Us
Our Approach
- What We Do
- Partnering
Patients & Providers
Products
Science & Pipeline
Investors
Careers
- Culture
- Job Openings
Contact
Home
Menu Menu

Press Releases

Overview
Events & Presentations
Stock Information
Press Releases
Corporate Governance
State Compliance
SEC Filings
- Quarterly Results
Contact
Email Alerts
FAQs

Year

Zevra Therapeutics Begins Trading as ZVRA

03-01-2023
Zevra Therapeutics Reiterates Commitment to Rare Disease Community as New Corporate Council Member of the National Organization for Rare Disorders (NORD)

02-28-2023
Zevra Therapeutics, a Rare Disease Therapeutics Company, Files Preliminary Proxy

02-27-2023
Zevra Therapeutics to Report Fourth Quarter and Full-Year 2022 Results

02-27-2023
Zevra Therapeutics Announces Arimoclomol Research Featured in Two Poster Presentations at the 19th Annual WORLDSymposium™ 2023

02-24-2023
Zevra Therapeutics Announces Two Abstracts Accepted for Presentation at the 19th Annual WORLDSymposium™ 2023

02-23-2023
CORRECTION – KemPharm Announces Corporate Name Change to Zevra Therapeutics

02-22-2023
KemPharm Enhances Senior Management Team

01-31-2023
KemPharm Issues Letter to Shareholders

01-24-2023
KemPharm Partners with the Hypersomnia Foundation to Support Sleep Disorder Research and Advocacy

01-18-2023

Pagination

First page
Previous page
…
Page 6
Page 7
Current page 8
Page 9
Page 10
…
Next page
Last page

About Us
Our Approach
- What We Do
- Partnering
Patients & Providers
Products
Science & Pipeline
Investors
Careers
- Culture
- Job Openings
Contact
Home

© 2024 Zevra Therapeutics, Inc. All rights reserved. Privacy Policy | Terms of Use